Catalyst Pharmaceuticals (CPRX) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to -$689.9 million.
- Catalyst Pharmaceuticals' Enterprise Value fell 5596.74% to -$689.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$689.9 million, marking a year-over-year decrease of 5596.74%. This contributed to the annual value of -$517.6 million for FY2024, which is 27603.03% down from last year.
- Catalyst Pharmaceuticals' Enterprise Value amounted to -$689.9 million in Q3 2025, which was down 5596.74% from -$652.8 million recorded in Q2 2025.
- In the past 5 years, Catalyst Pharmaceuticals' Enterprise Value ranged from a high of -$121.0 million in Q3 2023 and a low of -$689.9 million during Q3 2025
- Its 5-year average for Enterprise Value is -$304.9 million, with a median of -$220.8 million in 2022.
- In the last 5 years, Catalyst Pharmaceuticals' Enterprise Value surged by 5387.46% in 2023 and then plummeted by 27603.03% in 2024.
- Quarter analysis of 5 years shows Catalyst Pharmaceuticals' Enterprise Value stood at -$191.3 million in 2021, then crashed by 56.01% to -$298.4 million in 2022, then surged by 53.87% to -$137.6 million in 2023, then plummeted by 276.03% to -$517.6 million in 2024, then tumbled by 33.3% to -$689.9 million in 2025.
- Its Enterprise Value stands at -$689.9 million for Q3 2025, versus -$652.8 million for Q2 2025 and -$580.7 million for Q1 2025.